$30 Billion Deal, page-3280

IMHO you have got it right. If BIT225 had proved ineffective, that would have been known very early on and it would have been 'game over' long ago. However, if it is possible that the "cure" word might be applicable, then that has to be validated against all known markers, and then some. Biotron's Medical Advisory Board would also likely need to give their concurrence. Plus, the FDA, Big Pharma and others will want to know just how the drug works to achieve its results. That's a lot of testing over three concurrent trials dealing with a variety of viral mutations.
GLATH.